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Excessive trabeculation of human left ventricles (LV) has been found in both pediatric and 
adult patients, with or without manifest cardiac disease. Presence of excessive trabeculations 
together with extensive inter-trabecular spaces that communicate with the ventricular cavity 
and a thin and ‘compacted’ myocardium points to a diagnosis of left ventricular non-
compaction (LVNC). However, a global consensus on diagnosis, management or even the 
existence of this condition as a separate entity is lacking at present. 
The capability of cardiac magnetic resonance (CMR) imaging to visualize trabeculae 
at high-spatial resolution has led to several quantification methods and LVNC diagnostic 
criteria, ranging from measurements of trabeculae length and total trabeculae mass to the 
fractal dimension technique (1-3). However, overreliance on imaging criteria for LVNC 
poses the risk of false diagnosis which will have tremendous impact on patients and their 
families. Therefore, it is vital to address 2 key questions. 1) What is the prognostic value of 
excessive trabeculation in an asymptomatic low risk population with normal cardiac 
morphology and function? 2) Is the extent of trabeculation important in the context of 
cardiovascular disease? 
In this issue of JACC, Weir-McCall and colleagues described a cross-sectional 
analysis of association between excessive LV trabeculation meeting the current diagnostic 
criteria for LVNC and a variety of demographic, clinical and LV parameters in 1,480 
asymptomatic participants (TASCFORCE cohort) free from known cardiovascular diseases. 
This study found that a significant proportion of the cohort (15%) met >1 of the current 
CMR-based LVNC diagnostic criteria. In addition, in multivariate analysis the long-axis non-
compaction to compaction ratio was negatively correlated with systolic blood pressure and 
LV mass, even though the effect sizes were minimal and unlikely to have any clinical 
significance. These results echoed the previous study by our group published in this Journal, 
where we demonstrated similar findings of high prevalence of excessive trabeculation in the 
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asymptomatic multi-ethnic study of atherosclerosis (MESA) cohort, which appeared to have 
clinically insignificant influence on prognostically important LV parameters (4). It would 
certainly be interesting to see if those with excessive trabeculation in the TASCFORCE 
cohort develop adverse clinical outcomes at the planned 10-year follow-up, but our own data 
from the larger MESA study (sample size of ~3,000) showed that the event rates in an 
otherwise healthy cohort were too low for any definitive conclusion. 
Most published literature on poor clinical outcomes of pediatric LVNC were 
relatively small in sample size and retrospective in nature, and the prognostic value of extent 
of trabeculation was not assessed (5-7). A recent paper by Claudia Stöllberger et al. described 
an excellent summary on co-morbidities and prognosis of published adult LVNC studies (8). 
These studies were also relatively small in size (maximum 220 participants) and typically 
consisted of patients with abnormal heart function or pre-existing cardiac symptoms. The 
adverse event rates were extremely variable in these studies and the extent of trabeculation 
was not found to be an independent predictor of major adverse cardiovascular events. 
This issue of JACC presents an article by Daniele Andreini et al. which sheds further 
light on the prognostic relevance of the extent of trabeculation measured by CMR. In this 
prospective multicenter observational study, 113 patients with imaging evidence of LVNC 
were followed up for a composite endpoint of adverse cardiovascular outcomes—
thromboembolic events, heart failure hospitalization, ventricular arrhythmias or cardiac 
death—over a course of approximately 4 years. It is important to note that a significant 
proportion of the study cohort had impaired cardiac function at recruitment with mean LV 
ejection fraction of 45%. Those with high clinical pre-test probability of LVNC made up 74% 
of the cohort. Thirty-six patients met the primary endpoint and 97% of those with events 
belonged to the high clinical pre-test probability group. The extent of trabeculation quantified 
by CMR was not associated with clinical outcome in the whole cohort. In multivariate 
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analysis, LV dilatation and presence of late gadolinium enhancement (LGE) were the only 
significant independent CMR predictors of adverse outcomes. In fact, none of the event-free 
patients had abnormal LV volumes or LGE. 
These findings have important clinical implications. First, features of high pre-test 
probability of cardiomyopathy—cardiac symptoms, positive family history of non-ischemic 
cardiomyopathy, neuromuscular diseases, or prior malignant arrhythmias and 
thromboembolic events—are excellent predictors of adverse outcomes in those patients with 
excessive trabeculation. Second, the extent of trabeculation alone does not have any 
additional prognostic implication above and beyond the well-established deleterious markers, 
such as LV dilatation or LGE. The latter finding also reinforces the expanding pool of 
evidence suggesting trabeculation as an epiphenomenon coexisting with other forms of 
cardiomyopathies such as dilated cardiomyopathy (DCM) (9).  
These 2 timely papers and previous literature highlight the absence of convincing 
evidence to consider the degree of trabeculation as prognostically relevant in asymptomatic 
low risk populations and in cardiomyopathies. This conclusion leads to further open 
questions on whether our current trabeculation quantification or LVNC diagnostic criteria are 
adequate for diagnosis and risk stratification and perhaps, more importantly, on the existence 
of LVNC as a separate disease entity. 
The nomenclature of LVNC implies that the ‘compact’ or ‘solid’ layer of the 
myocardium develops through coalescing of pre-existing embryonic trabeculation. However, 
the emerging evidence suggests that this commonly-held belief of the mode of compact 
myocardium development is incorrect except for the papillary muscles (10). Using molecular 
staining techniques, studies by de Boer et al. and Sizarov et al. demonstrated the role of 
cellular proliferation within the solid myocardium during embryonic cardiogenesis in mouse 
and human, which contradicts the theory of trabecular condensation in formation of compact 
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myocardium (11,12). If trabeculation is indeed important for the size of compact wall, we 
should expect the compact wall thickness to be negatively correlated with degree of 
trabeculation. However, the inverse was true in our data from the MESA study (Figure 1). A 
seminal paper by Jensen and colleagues examined the evolution of ventricular trabeculation 
in both endothermic (warm-blooded) and ectothermic (cold-blooded) species (13). They 
found that the hypertrabeculated ventricles in post-natal human hearts were far less 
trabeculated than the embryonic ventricles. In contrast, the ventricles of fully-formed cold-
blooded vertebrate were as trabeculated as their embryonic counterparts. These findings 
greatly challenge the hypothesis of LVNC as persistence of embryonic design at least in 
warm-blooded vertebrates and the term LVNC itself may be a misnomer. 
In summary, there is growing evidence in the literature that presence of excessive 
trabeculation has no meaningful independent prognostic value in asymptomatic low risk 
populations and in cardiomyopathies, particularly DCM, when other prognostic factors are 
considered in regression models. Compaction does not appear to be an important process for 
formation of the solid ventricular wall and it may be the opportune time to reconsider the 
term “LVNC” and maybe use a preferable term such as ‘excessive trabeculation’ instead. 
Further research is needed to investigate if the extent of trabeculation plays an important 
prognostic role in physiological remodeling and in non-DCM cardiomyopathies. 
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FIGURE LEGEND 
Figure 1. Correlation between extent of trabeculation and compact myocardium thickness  
A – Expected relationship; B – Observed relationship in MESA data 
 

